Inconsistent post-translational modifications lead to batch rejection and reduced therapeutic efficacy. These innovations stabilize glycan profiles through metabolic pathway engineering and high-resolution mass spectrometry feedback.
Inaccurate assessment of how mutations impact protease activity and antibody binding strength leads to high experimental failure rates. Precise stability forecasting reduces the risk of protein degradation and functional loss during enrichment.